Cachexia News and Research

RSS
Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and muscle mass in people who are not trying to lose weight.
Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Moderate exercise on a regular basis may improve cancer treatments

Moderate exercise on a regular basis may improve cancer treatments

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Scientists discover sign of early development of pancreatic cancer

Scientists discover sign of early development of pancreatic cancer

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

Study pinpoints molecular cause of cachexia, hints at a potential treatment

Study pinpoints molecular cause of cachexia, hints at a potential treatment

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Study highlights impact of diet, exercise on prevention, treatment and survivorship of cancer

Study highlights impact of diet, exercise on prevention, treatment and survivorship of cancer

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

New antibody could boost strength, muscle mass in patients with cancer and other diseases

New antibody could boost strength, muscle mass in patients with cancer and other diseases

Chronic bronchitis could indicate COPD subtype

Chronic bronchitis could indicate COPD subtype

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting